Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 361 across all filing types
Latest filing 2025-11-06 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory filing used by listed companies to report monthly movements in securities, including share repurchases (treasury shares) and changes in issued share capital. While it details share buybacks, it is a recurring regulatory disclosure required by the Exchange Listing Rules rather than a standalone 'Transaction in Own Shares' announcement. Given the specific nature of the HKEX Monthly Return, it falls under the 'Regulatory Filings' category as a standard periodic disclosure.
2025-11-06 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a formal Hong Kong Exchange FF305 “Next Day Disclosure Return” detailing the issuer’s own share transactions (repurchase of shares held as treasury shares, repurchase prices, aggregate amounts, mandate details). It is not an earnings release, annual report, or management change notice. It clearly reports the company’s share buyback activity under Listing Rule 13.25A. This matches the “Transaction in Own Shares” category (Code: POS).
2025-10-28 English
VOLUNTARY ANNOUNCEMENT - JSKN003 WAS GRANTED FTD BY THE U.S. FDA FOR THE TREATMENT OF PROC
Regulatory Filings Classification · 1% confidence The document is a “Voluntary Announcement” by Alphamab Oncology on the HKEX platform regarding a Fast Track Designation by the U.S. FDA and other clinical development updates. It does not present financial results or periodic reporting, nor is it a management change or capital raising notice. It is a general corporate/regulatory press release that does not fit any of the more specific categories (e.g., ER, IR, CAP, etc.). Therefore it falls into the fallback “Regulatory Filings” category (RNS).
2025-10-27 English
GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares Classification · 1% confidence The document is an announcement of a grant of award shares under the Company’s restricted share award scheme to directors and an employee, detailing the share issuance, vesting schedule, and related mechanics. This is not a general fundraising or capital markets transaction, but rather the Company selling/issuing its own shares to insiders. Under our taxonomy, this fits “Transaction in Own Shares (POS)” which covers share repurchase and issuance announcements.
2025-10-24 English
VOLUNTARY ANNOUNCEMENT - JSKN003 WAS GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION BY THE CDE
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement by Alphamab Oncology regarding a breakthrough therapy designation for its product JSKN003. It is not a financial report (e.g., annual, quarterly, earnings), nor a governance/shareholder vote notice, nor a capital/financing update, nor an investor presentation. It is a general regulatory/business update that does not fit any more specific category, so it falls under the fallback category of Regulatory Filings (RNS).
2025-10-20 English
VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES OF JSKN003 FOR PRESENTATION AT ESMO CONGRESS 2025
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by Alphamab Oncology on the Hong Kong Stock Exchange, providing research updates of its clinical asset JSKN003 presented at a medical congress. It is not an AGM material, financial report, earnings release, management change, or any other structured regulatory form—it is essentially a business update/press release. Therefore, it falls under the fallback "Regulatory Filings" category (RNS).
2025-10-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.